Two Sigma Advisers
AQST icon

Two Sigma Advisers’s Aquestive Therapeutics AQST Stock Holding History

Two Sigma Advisers’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-332,400
Closed -$2.15M – 151
2025
Q4 		$2.15M Buy
+332,400
New +$2.07M ﹤0.01% 1160
2025
Q3 		– Sell
-551,700
Closed -$1.83M – 2347
2025
Q2 		$1.83M Sell
551,700
-24,700
-4% -$70.9K ﹤0.01% 1164
2025
Q1 		$1.67M Buy
576,400
+560,400
+3,503% +$1.7M ﹤0.01% 1234
2024
Q4 		$57K Buy
+16,000
New +$73.8K ﹤0.01% 2272
2024
Q3 		– Sell
-24,200
Closed -$62.9K – 2277
2024
Q2 		$62.9K Buy
24,200
+9,400
+64% +$31.4K ﹤0.01% 2348
2024
Q1 		$63K Sell
14,800
-12,000
-45% -$39.9K ﹤0.01% 2336
2023
Q4 		$54.1K Sell
26,800
-3,300
-11% -$5.83K ﹤0.01% 2395
2023
Q3 		$46.1K Buy
30,100
+1,700
+6% +$2.92K ﹤0.01% 2283
2023
Q2 		$46.9K Buy
28,400
+5,300
+23% +$9.59K ﹤0.01% 2280
2023
Q1 		$26.3K Sell
23,100
-9,300
-29% -$8.06K ﹤0.01% 2502
2022
Q4 		$29.2K Sell
32,400
-7,500
-19% -$7.04K ﹤0.01% 2404
2022
Q3 		$47K Sell
39,900
-8,000
-17% -$9.04K ﹤0.01% 2377
2022
Q2 		$31K Sell
47,900
-4,500
-9% -$5.99K ﹤0.01% 2516
2022
Q1 		$137K Sell
52,400
-9,400
-15% -$27.5K ﹤0.01% 2447
2021
Q4 		$240K Buy
61,800
+14,500
+31% +$72.8K ﹤0.01% 2221
2021
Q3 		$206K Buy
47,300
+10,900
+30% +$42.7K ﹤0.01% 2240
2021
Q2 		$145K Buy
36,400
+25,200
+225% +$101K ﹤0.01% 2310
2021
Q1 		$58K Buy
+11,200
New +$59.6K ﹤0.01% 2493
2020
Q4 		– Sell
-17,500
Closed -$85K – 2379
2020
Q3 		$85K Sell
17,500
-6,300
-26% -$41.2K ﹤0.01% 2283
2020
Q2 		$116K Buy
23,800
+6,500
+38% +$29.9K ﹤0.01% 2342
2020
Q1 		$38K Buy
17,300
+6,300
+57% +$23.9K ﹤0.01% 2390
2019
Q4 		$64K Buy
+11,000
New +$57.2K ﹤0.01% 2280

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers's AQST Position: Q1 2026 in Review

Two Sigma Advisers sold out of Aquestive Therapeutics (AQST) in Q1 2026, closing a stake of 332,400 shares — an estimated $2.15M sold.

Two Sigma Advisers first reported a position in AQST in Q4 2019 and held it in 22 quarters. The position peaked at $2.15M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Two Sigma Advisers reported no remaining Aquestive Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 332,400 Aquestive Therapeutics shares in Q1 2026, an estimated $2.15M.
  • Two Sigma Advisers first reported a position in Aquestive Therapeutics in Q4 2019 and held it in 22 quarters.
  • Two Sigma Advisers's Aquestive Therapeutics position peaked at $2.15M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.